Oxford Global, London, United Kingdom
09th & 10th November 2015
Oxford Global Conferences are proud to present our Cell & Gene Therapy Congress, taking place on the 9th & 10th November 2015. This event will be co-located with our prestigious 4th Annual Cell Culture & Bioprocessing Congress, as well as our 2nd Annual Stem Cell Congress. Over 170 delegates will represent leading biotech companies, global pharma organisations and internationally renowned academic institutions.
Over 20 presentations, case studies and panel discussions will focus on the key issues in cell & gene therapy, from development and bioprocessing optimisation to commercial production.
2 interactive streams: - Cell & Gene Therapy: Development, Clinical Trials & Commercialisation - Cell Therapy Bioprocessing
The first day of the conference will look at the development of cell therapies, as well as clinical trial case studies and strategies for commercialisation of successful treatments. The latest developments in the use of gene-editing tools such as CRISPR, TALEN and ZFN will be one of the highlights of the discussions, as well as potential business models for new products. Our second day will focus on the challenges associated with the bioprocessing and manufacture of cell therapies. Hot topics will include approaches to effective scale-up of cell and gene therapies, as well as cutting edge technologies and solutions for manufacture and the latest both upstream and downstream processing. Over two days, the congress will attract senior-level decision makers working at the forefront of the cell therapy industry from the US and Europe. The conference programme consists of world-class keynote addresses, industry and academic led presentations and panel debates, as well as ample networking opportunities, creating an interactive platform for high-level scientific and business discussion.
|
|
Invited Speakers:
|
|
- Gwen Binder-Scholl
Executive VP, Adaptimmune - Karen Ellison
Head of Commercial, Cell Therapy Catapult - Paul Fairchild
Professor, Sir William Dunn School of Pathology, University of Oxford - Keith Foster
Professor Translational Medicine, University of Reading - Robert Hariri
Founder, Chairman & CSO, Celgene - Zsuzsanna Izsvak
Professor, MDC Berlin - Karen Kozarsky
VP Research & Development, ReGenX Biosciences - John McGrath
Professor of Molecular Dermatology, King’s College London - Charles Sentman
Professor, Microbiology & Immunology, Geisel School of Medicine - Katherine Tsokas
Senior Director, Global Regulatory Affairs, Janssen R & D - Gabor Veres
Vice President Pre-Clinical Research, Bluebird Bio
|
|